[{"address1": "7707 Gateway Boulevard", "address2": "Suite 140", "city": "Newark", "state": "CA", "zip": "94560-1160", "country": "United States", "phone": "510 474 0170", "website": "https://www.protagonist-inc.com", "industry": "Biotechnology", "sector": "Healthcare", "longBusinessSummary": "Protagonist Therapeutics, Inc., a biopharmaceutical company, develops peptide-based drugs for hematology and blood disorders, and inflammatory and immunomodulatory diseases. It is developing Rusfertide (PTG-300), an injectable hepcidin mimetic that completed phase 2 clinical trials for the treatment of polycythemia vera and other blood disorders; and JNJ-2113, an orally delivered investigational drug to block biological pathways that completed phase 2b clinical trials for the treatment of moderate-to-severe plaque psoriasis; and PN-943, an orally delivered, gut-restricted alpha 4 beta 7 specific integrin antagonist completed a phase 2 clinical trials in patients with moderate to severe ulcerative colitis. The company has a license and collaboration agreement with Takeda to commercialize rusfertide; and JNJ Innovative Medicines to co-develop Interleukin-23 receptor antagonist compound JNJ-2113. Protagonist Therapeutics, Inc. was incorporated in 2006 and is headquartered in Newark, California.", "fullTimeEmployees": 126, "companyOfficers": [{"maxAge": 1, "name": "Dr. Dinesh V. Patel Ph.D.", "age": 66, "title": "CEO, President, Secretary & Director", "yearBorn": 1957, "fiscalYear": 2023, "totalPay": 1026472, "exercisedValue": 0, "unexercisedValue": 10583697}, {"maxAge": 1, "name": "Mr. Asif  Ali", "age": 49, "title": "Executive VP & Chief Financial Officer", "yearBorn": 1974, "fiscalYear": 2023, "totalPay": 631042, "exercisedValue": 0, "unexercisedValue": 285755}, {"maxAge": 1, "name": "Dr. Suneel K. Gupta Ph.D.", "age": 65, "title": "Chief Development Officer", "yearBorn": 1958, "fiscalYear": 2023, "totalPay": 719206, "exercisedValue": 0, "unexercisedValue": 2986052}, {"maxAge": 1, "name": "Dr. Mark  Smythe Ph.D.", "age": 58, "title": "Founder & VP Technology", "yearBorn": 1965, "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. Mohammad  Masjedizadeh Ph.D.", "title": "Executive VP & Chief Technical Officer", "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. Matthew M. Gosling", "age": 52, "title": "Executive VP & General Counsel", "yearBorn": 1971, "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Ms. Carena  Spivey", "title": "Head of HR & Senior VP of Human Resources", "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Dr. Ashok  Bhandari Ph.D.", "age": 59, "title": "Executive VP & Chief Drug Discovery and Preclinical Development Officer", "yearBorn": 1964, "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. Carter J. King", "age": 52, "title": "Executive Vice President of Business Development", "yearBorn": 1971, "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Ms. Abha  Bommireddi", "title": "Executive Vice President of Portfolio & Program Management", "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}], "auditRisk": 8, "boardRisk": 7, "compensationRisk": 9, "shareHolderRightsRisk": 7, "overallRisk": 8, "governanceEpochDate": 1730419200, "compensationAsOfEpochDate": 1703980800, "maxAge": 86400, "priceHint": 2, "previousClose": 47.61, "open": 48.86, "dayLow": 45.265, "dayHigh": 48.86, "regularMarketPreviousClose": 47.61, "regularMarketOpen": 48.86, "regularMarketDayLow": 45.265, "regularMarketDayHigh": 48.86, "beta": 2.163, "trailingPE": 16.872263, "forwardPE": -32.32867, "volume": 682762, "regularMarketVolume": 682762, "averageVolume": 602010, "averageVolume10days": 523170, "averageDailyVolume10Day": 523170, "bid": 46.09, "ask": 46.33, "bidSize": 200, "askSize": 100, "marketCap": 2755215616, "fiftyTwoWeekLow": 15.05, "fiftyTwoWeekHigh": 48.89, "priceToSalesTrailing12Months": 8.509135, "fiftyDayAverage": 45.5374, "twoHundredDayAverage": 35.0805, "currency": "USD", "enterpriseValue": 2297395456, "profitMargins": 0.52765, "floatShares": 44199082, "sharesOutstanding": 59598000, "sharesShort": 3001498, "sharesShortPriorMonth": 3229183, "sharesShortPreviousMonthDate": 1726185600, "dateShortInterest": 1728950400, "sharesPercentSharesOut": 0.051, "heldPercentInsiders": 0.01176, "heldPercentInstitutions": 1.07441, "shortRatio": 4.19, "shortPercentOfFloat": 0.0517, "bookValue": 8.936, "priceToBook": 5.1734557, "lastFiscalYearEnd": 1703980800, "nextFiscalYearEnd": 1735603200, "mostRecentQuarter": 1727654400, "netIncomeToCommon": 170848992, "trailingEps": 2.74, "forwardEps": -1.43, "enterpriseToRevenue": 7.095, "enterpriseToEbitda": 15.309, "exchange": "NGM", "quoteType": "EQUITY", "symbol": "PTGX", "underlyingSymbol": "PTGX", "shortName": "Protagonist Therapeutics, Inc.", "longName": "Protagonist Therapeutics, Inc.", "firstTradeDateEpochUtc": 1470922200, "timeZoneFullName": "America/New_York", "timeZoneShortName": "EST", "uuid": "db1f1c69-f5b8-3245-b848-39f5038697fa", "gmtOffSetMilliseconds": -18000000, "currentPrice": 46.23, "targetHighPrice": 65.0, "targetLowPrice": 43.0, "targetMeanPrice": 54.86, "targetMedianPrice": 57.0, "recommendationMean": 1.7, "recommendationKey": "buy", "numberOfAnalystOpinions": 7, "totalCash": 468720992, "totalCashPerShare": 7.865, "ebitda": 150068000, "totalDebt": 10900000, "quickRatio": 10.574, "currentRatio": 10.695, "totalRevenue": 323795008, "debtToEquity": 2.049, "revenuePerShare": 5.3, "returnOnAssets": 0.19959, "returnOnEquity": 0.40967998, "freeCashflow": 144935008, "operatingCashflow": 230290000, "grossMargins": 1.0, "ebitdaMargins": 0.46347, "operatingMargins": -8.86695, "financialCurrency": "USD", "trailingPegRatio": null, "__fetch_time": "2024-11-11"}]